Clinical Trials Browser

Active not recruiting × Carcinoma, Non-Small-Cell Lung × dostarlimab × Clear all

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02715284 2026-01-13

GARNET

Phase 1 Active not recruiting

730 enrolled 3 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05565378 2026-01-08

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Phase 2 Active not recruiting

351 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

463 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04655976 2025-09-26

COSTAR Lung

Phase 3 Active not recruiting

758 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06472076 2025-09-10

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

88 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

GARNET

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

COSTAR Lung

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)